A Phase 2, international, multicenter, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (Oral Azacitidine) Alone and in combination with the Durvalumab (MEDI14736) in subjects with Myelodysplastic Syndromes who fail to achieve an Objective response to treatment with Azacitidine for Injection of Decitabine